Dianthus Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-50.2M | $-40.8M | $-64.4M | $-36.8M | $-31.6M | $-29.5M | $-28.4M | $-25.2M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $37.0K | $32.0K | $27.0K | $27.0K | $30.0K | $27.0K | $26.0K | $25.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $11.9M | $10.6M | $6.0M | $5.8M | $5.7M | $5.3M | $3.9M | $3.8M |
| Net Cash from Operating Activities | $-49.0M | $-28.9M | $-47.0M | $-30.6M | $-23.9M | $-27.6M | $-27.4M | $-21.3M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-478.5M | $-134.0M | $37.2M | $-201.3M | $26.4M | $14.8M | $-23.1M | $-259.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $10.4M | $739.4M | $4.9M | $274.5M | $568.0K | $161.0K | $39.7M | $296.0K |
| Net Change in Cash | $-517.1M | $576.6M | $-4.9M | $42.7M | $3.1M | $-12.7M | $-10.9M | $-280.3M |
| Free Cash Flow | — | — | — | — | — | — | — | — |